Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

OBJECTIVES: The randomized Phase IIIb/IV EXTEND trial showed that extended-pulsed fidaxomicin significantly improved sustained clinical cure and reduced recurrence versus vancomycin in patients ≥60 years old with Clostridium difficile infection (CDI). Cost-effectiveness of extended-pulsed fidaxomici...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornely, Oliver A, Watt, Maureen, McCrea, Charles, Goldenberg, Simon D, De Nigris, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105871/
https://www.ncbi.nlm.nih.gov/pubmed/29800295
http://dx.doi.org/10.1093/jac/dky184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105871/
https://www.ncbi.nlm.nih.gov/pubmed/29800295
http://dx.doi.org/10.1093/jac/dky184

Ejemplares similares